10-Q: HeartBeam Reports Q1 2024 Results, Progresses Towards FDA Clearance

HeartBeam, Inc. reported its Q1 2024 financial results, highlighting increased R&D spending and progress towards FDA clearance for its AIMIGo device.

Summary

• HeartBeam, Inc. is a cardiac technology company focused on developing ambulatory ECG solutions.
• The company's proprietary VECG technology aims to provide 3D images of cardiac electrical activity.
• HeartBeam is seeking FDA clearance for its initial telehealth products, including the AIMIGo device.
• The company filed a 510(k) submission in 2023 for an ambulatory device that synthesizes a 12L ECG.
• For the three months ended March 31, 2024, the company reported a net loss of $4.6 million, or $0.17 per share.
• Operating expenses totaled $4.8 million, with $2.4 million in general and administrative costs and $2.4 million in research and development.
• The company's cash and cash equivalents balance was $12.6 million as of March 31, 2024.
• HeartBeam believes its current cash is insufficient to fund operations for the next twelve months.
• The company entered into a new sales agreement with Public Ventures, LLC to sell up to $17 million of common stock.
• HeartBeam expects no material commercial revenue in 2024.

Sentiment

Score: 4

Explanation: The document highlights progress in technology development and clinical trials, but the financial situation and going concern issues raise significant concerns. The company is burning through cash and needs to raise more capital. The lack of revenue and material weaknesses in internal controls further dampen the sentiment.

Positives

• The company is progressing towards FDA clearance for its AIMIGo device, with anticipated clearance by the end of Q2 2024.
• HeartBeam has made significant progress in its clinical study, enrolling more than 50% of patients.
• The company has an active AI program with deep learning algorithms focused on detecting cardiac arrhythmias.
• HeartBeam has been granted two new U.S. patents, strengthening its intellectual property portfolio.
• The company's VECG technology has demonstrated similar accuracy to a standard 12L ECG in detecting coronary occlusions.

Negatives

• The company has incurred losses each year since inception and has experienced negative cash flows from operations.
• HeartBeam's existing cash is insufficient to fund operations for the next twelve months.
• The company expects no material commercial revenue in 2024.
• The company's disclosure controls and procedures were not effective as of March 31, 2024.
• The company has identified material weaknesses in its internal controls.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is no assurance that financing or strategic relationships will be available on acceptable terms.
• The company is subject to risks similar to those of early-stage medical device companies, including regulatory approvals and competition.
• The company's products require FDA clearance and have not been cleared for marketing.
• The company's clinical trial costs are expected to approximate $0.8 million.

Future Outlook

HeartBeam anticipates FDA clearance for its AIMIGo device by the end of Q2 2024 and expects to submit a second 510(k) application by Q3 2024. The company plans a limited launch of AIMIGo by the end of 2024. HeartBeam expects no material commercial revenue in 2024.

Management Comments

• The company believes that its products and services will benefit many stakeholders, including patients, healthcare providers, and healthcare payors.
• The company believes that it is uniquely positioned to play a central role in ambulatory cardiac monitoring.
• The company is encouraged by early discussions with industry players and their interest in its technology.
• The company's management team and additional personnel will be primarily responsible for executing and implementing growth opportunities.

Industry Context

HeartBeam is operating in the rapidly growing field of ambulatory cardiac health monitoring. The company's VECG technology and AI program position it to compete with existing ambulatory monitoring solutions. The company's focus on high-risk Coronary Artery Disease (CAD) patients aligns with the increasing need for advanced cardiac monitoring solutions.

Comparison to Industry Standards

• HeartBeam's VECG technology has demonstrated similar accuracy to a standard 12L ECG in detecting coronary occlusions, as shown in a study published in JACC: Advances.
• The company's AI algorithms have shown improved performance in the detection of atrial flutter over single-lead ECGs and similar performance to 12L ECGs.
• The company's technology aims to provide a more accurate and convenient solution for ambulatory cardiac monitoring compared to traditional hospital-based ECG systems.
• The company's approach of synthesizing a 12L ECG from a 3-lead device is innovative and could potentially disrupt the market for ambulatory cardiac monitoring.
• The company's focus on AI and deep learning algorithms could provide additional value to patients and physicians in the long run.

Related Party Transactions

• The company obtained accounting services from CTRLCFO, a firm in which an executive of the Company had significant influence until February 1, 2024.

Stakeholder Impact

• Shareholders are impacted by the company's financial losses and the need for additional capital.
• Employees are impacted by the company's financial situation and the potential for future changes.
• Customers and healthcare providers are impacted by the company's progress towards FDA clearance and the potential for new cardiac monitoring solutions.
• Suppliers and creditors are impacted by the company's financial situation and its ability to meet its obligations.

Next Steps

• The company plans to complete enrollment in the VALID-ECG study in Q2 2024.
• The company plans to submit the second 510(k) application by Q3 2024.
• The company anticipates a limited launch of AIMIGo by the end of 2024.
• The company will continue to assess and remediate the material weaknesses in its internal controls.
• The company will continue to seek additional capital through various potential sources.

Key Dates

Keywords

ECG, VECG, HeartBeam, AIMIGo, FDA clearance, cardiac monitoring, telehealth, clinical trial, AI, arrhythmia, medical device, 510(k)